Back to Search Start Over

Aldeyra shows FDA-rejected reproxalap improves eye discomfort in new phase 3 study.

Authors :
Masson, Gabrielle
Source :
FierceBiotech; 8/8/2024, pN.PAG-N.PAG, 1p
Publication Year :
2024

Abstract

After an FDA rejection last year, Aldeyra has scored a(nother) phase 3 win for dry eye drug reproxalap. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
DRY eye syndromes
THERAPEUTICS
DRUGS

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
178936097

Tools

Authors Abstract Subjects Details